tirzepatide type of drug Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Oral Tirzepatide | Tablet Health

Hypoglycemia (low blood sugar) may also occur, particularly when combined with other diabetes medications that boost insulin production

Measuring urine and serum ketone levels in patients with gastrointestinal symptoms who are taking dual GLP-1 and GIP receptor agonists is necessary, and stopping the medication is necessary when needed

Some products sold as "oral tirzepatide" actually contain different peptides or compounds entirely

For example, studies indicate that substantial weight reduction often takes place over 20 to 72 weeks, with the most significant changes observed later in the treatment period

In the absence of identifiable organic causes of hypoglycemia, and in light of the patient's complex gastrointestinal history and dependence on parenteral nutrition with limited oral intake, a defect in incretin secretion or action was hypothesized as a potential contributor to her glycemic instability

Tirzepatide (Mounjaro) is a game changer in obesity and type 2 diabetes treatment